Indivior (INDV) Stock Price, News & Analysis

Company Overview

Indivior PLC (NASDAQ: INDV) is a specialty pharmaceutical company focused on developing and commercializing treatments for substance use disorders and serious mental health conditions. The company’s primary focus is opioid use disorder, with products designed to support patients through medication-assisted treatment and recovery.

Indivior’s portfolio includes Sublocade, an extended-release injectable formulation of buprenorphine; Suboxone, a buprenorphine and naloxone product available in sublingual formulations; and Perseris, an extended-release injectable formulation of risperidone for schizophrenia. The company also markets Opvee, a nalmefene nasal spray intended for the emergency treatment of opioid overdose in adults and pediatric patients.

The company was established as an independent business in 2014 following its separation from Reckitt Benckiser. Indivior is headquartered in Richmond, Virginia, and serves patients and healthcare providers primarily in the United States, as well as in selected international markets. Its products are distributed through healthcare providers, pharmacies and other treatment channels.

Indivior is led by Chief Executive Officer Mark Crossley. The company continues to focus its research, development and commercial activities on expanding access to treatments for opioid use disorder and addressing other conditions associated with addiction and mental health.

Key Stats

• Today's Range: $33.99 to $36.30
• 50-Day Range: $34.16 to $39.43
• 52-Week Range: $23.72 to $42.81
• Volume: 2.78 million shs
• Average Volume: 2.42 million shs
• Market Capitalization: $4.03 billion
• P/E Ratio: 12.24
• Dividend Yield: N/A
• Price Target: $45.17
• Consensus Rating: Buy

Indivior Stock Analysis - MarketRank™

Indivior scored higher than 92% of companies evaluated by MarketBeat, and ranked 38th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Buy

Consensus Rating

Indivior has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 5 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Indivior has a consensus price target of $45.17, representing about 32.2% upside from its current price of $34.16.

Amount of Analyst Coverage

Indivior has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 4.64%

Earnings Growth

Earnings for Indivior are expected to grow by 4.64% in the coming year, from $3.66 to $3.83 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Indivior is 12.24, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 36.26.

Price to Earnings Ratio vs. Sector

The P/E ratio of Indivior is 12.24, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 216.61.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.89% of the float of Indivior has been sold short.

Short Interest Ratio / Days to Cover

Indivior has a short interest ratio ("days to cover") of 5.26.

Change versus previous month

Short interest in Indivior has recently decreased by 6.79%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Indivior does not currently pay a dividend.

Dividend Growth

Indivior does not have a long track record of dividend growth.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.28

News Sentiment

Indivior has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Indivior this week, compared to 3 articles on an average week.

Search Interest

Only 6 people have searched for INDV on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

5 people have added Indivior to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.9 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $107,955.00 in company stock, which represents 0.0027% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Indivior insiders have bought more of their company's stock than they have sold. Specifically, they have bought $107,955.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

0.74% of the stock of Indivior is held by insiders.

Percentage Held by Institutions

60.33% of the stock of Indivior is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 6/30/2026
• Today: 10/15/2026
• EGM 2026: 10/15/2026
• Next Earnings (Estimated): 10/29/2026
• Record date for 11/6 Dividend: 10/30/2026
• Ex-Dividend for 11/6 Dividend: 10/30/2026
• Dividend Payable: 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:INDV
• CIK: 1625297
• Web: www.indivior.com
• Phone: 804-379-1090
• Fax: 804-379-1215
• Employees: 838
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Indivior: $45.17
• High Price Target: $53.00
• Low Price Target: $36.00
• Potential Upside/Downside: +32.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.79
• Trailing P/E Ratio: 12.24
• Forward P/E Ratio: 9.33
• P/E Growth: N/A
• Net Income: $210 million
• Net Margins: 26.65%
• Pretax Margin: 29.50%
• Return on Equity: -283.11%
• Return on Assets: 36.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.84
• Quick Ratio: 0.66

Sales & Book Value

• Annual Sales: $1.24 billion
• Price / Sales: 3.25
• Cash Flow: $2.62 per share
• Price / Cash Flow: 13.02
• Book Value: ($0.78) per share
• Price / Book: -43.79

Miscellaneous

• Outstanding Shares: 118,030,000
• Free Float: 117,159,000
• Market Cap: $4.03 billion
• Optionable: Not Optionable
• Beta: 0.87